Selz Capital LLC bought a new stake in Constellation Pharmaceuticals Inc (NASDAQ:CNST) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,959 shares of the company’s stock, valued at approximately $610,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Constellation Pharmaceuticals by 30.7% during the 2nd quarter. Vanguard Group Inc. now owns 530,331 shares of the company’s stock worth $6,513,000 after acquiring an additional 124,591 shares during the period. BlackRock Inc. boosted its position in shares of Constellation Pharmaceuticals by 13.0% in the 2nd quarter. BlackRock Inc. now owns 820,432 shares of the company’s stock worth $10,074,000 after purchasing an additional 94,107 shares during the last quarter. P.A.W. Capital Corp grew its stake in shares of Constellation Pharmaceuticals by 33.3% during the third quarter. P.A.W. Capital Corp now owns 160,000 shares of the company’s stock worth $1,034,000 after purchasing an additional 40,000 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Constellation Pharmaceuticals during the second quarter worth $329,000. Finally, Northern Trust Corp increased its holdings in Constellation Pharmaceuticals by 12.7% in the second quarter. Northern Trust Corp now owns 146,358 shares of the company’s stock valued at $1,797,000 after purchasing an additional 16,548 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors.
In related news, insider Adrian Senderowicz sold 27,232 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $30.91, for a total value of $841,741.12. Also, CFO Emma Reeve sold 65,626 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $30.91, for a total value of $2,028,499.66. Insiders sold a total of 317,971 shares of company stock valued at $10,976,079 over the last quarter. 43.70% of the stock is owned by insiders.
CNST has been the topic of several analyst reports. Royal Bank of Canada increased their target price on Constellation Pharmaceuticals to $42.00 and gave the company a “positive” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Constellation Pharmaceuticals in a research report on Tuesday, December 10th. Zacks Investment Research cut Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. ValuEngine cut Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Finally, Oppenheimer increased their price target on shares of Constellation Pharmaceuticals from $40.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $43.25.
Shares of CNST traded down $0.85 during trading hours on Thursday, reaching $37.86. The stock had a trading volume of 1,734 shares, compared to its average volume of 493,374. The company has a market cap of $1.60 billion, a P/E ratio of -7.71 and a beta of 6.79. Constellation Pharmaceuticals Inc has a 52 week low of $5.16 and a 52 week high of $59.49. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average of $42.92 and a 200 day moving average of $20.44.
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Wednesday, November 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. As a group, equities analysts expect that Constellation Pharmaceuticals Inc will post -2.99 earnings per share for the current year.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Article: What sectors are represented in the Nikkei Index?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.